In this study, we found that the BCCIP protein level is downregulated in 33% of 473 cases of breast cancers (49% among triple-negative vs 25% among non-TNBC, p = 3.86 × 10–7) and BCCIP loss tends to be exclusive with p53 mutations but concurrent with 53BP1 loss in triple-negative cases (Tables 1 and 2). This evidence concerns the gene TP53 and breast cancer.